Aurobindo Pharma Limited’s Board of Directors met on February 9, 2026, to approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. For the standalone results, the company reported a total revenue from operations of 2,747.28 Crores for the current quarter, representing a slight decline of 1.52% from 2,789.72 Crores in the previous quarter and a decrease of 5.81% from 2,916.63 Crores in the same quarter last year. Despite the revenue dip, profit after tax for the current quarter rose to 582.07 Crores, reflecting a marginal 0.12% increase from 581.37 Crores in the prior quarter and a significant 23.31% growth from 472.05 Crores in the corresponding quarter of the previous year. The board also approved the appointment of Dr. (Mrs.) Punita Kumar Sinha as an Additional Director designated as Non-Executive Independent Director for a three-year term starting February 9, 2026.

Aurobindo Pharma Limited, headquartered in Hyderabad, India, is a major integrated pharmaceutical company that develops, manufactures, and markets a diverse range of generic pharmaceuticals and active pharmaceutical ingredients (APIs) globally. The company operates in a single reportable segment: Pharmaceuticals. In recent strategic moves, the company announced its plan to acquire a 26% stake in Garuda Renewables Private Limited for 66 Crores to procure renewable energy from hybrid wind and solar sources. Additionally, the Board approved a scheme of amalgamation to merge its wholly-owned step-down subsidiary, Auro Vaccines Private Limited, into its wholly-owned subsidiary, Curateq Biologics Private Limited.